Today's Rundown Biogen strikes $877M Nightstar gene therapy buyout Off-the-shelf CAR-T and gene-editing player Precision Bio files $100M IPO Apellis resumes phase 3 AMD trials after addressing safety issue Verrica’s molluscum contagiosum treatment sails through phase 3 Zafgen nabs ex-Biogen executive Priya Singhal as new R&D chief Featured Story | | | Monday, March 4, 2019 Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies. The takeover will give Biogen control of clinical-phase ophthalmology assets that could get to market ahead of drugs in development at rival gene therapy shops. |
|
|
Top Stories Monday, March 4, 2019 Precision Bio files $100 million IPO for its off-the-shelf CAR-Ts after raising $110 million in a series B and signing a hepatitis B alliance with Gilead. Monday, March 4, 2019 Apellis Pharmaceuticals has resumed dosing in phase 3 trials of its treatment for an advanced form of age-related macular degeneration (AMD). The resumption follows modifications to the production process to cut the risk of the noninfectious inflammation that triggered the halt. Saturday, March 2, 2019 Verrica's lead candidate met its primary endpoints in a pair of phase 3 studies testing it in the skin infection molluscum contagiosum. The treatment beat out placebo in completely clearing treatable lesions and reducing the number of lesions in both studies. Monday, March 4, 2019 Former Biogen executive Priya Singhal has joined Zafgen as its new head of research and development. She comes to the role after helping shepherd several programs toward regulatory filings and approvals. Resources Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! Calling Europe – Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 